update
Juno trial restart positive, but CAR-T sector still on a learning curve says TxCell
The US FDA’s decision to let Juno Therapeutics restart its JCAR015 trial is positive, but the CAR-T sector must learn from safety and efficacy findings says French biotech TxCell.